research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-05. Numbers and descriptions here follow the published literature rather than marketing material.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Vascular spasm: Vasoconstriction is produced by vascular smooth muscle cells, and is the blood vessel's first response to injury. The smooth muscle cells are controlled by vascular endothelium, which releases intravascular signals to control the contracting properties. When a blood vessel is damaged, there is an immediate reflex, initiated by local sympathetic pain receptors, which helps promote vasoconstriction. The damaged vessels will constrict (vasoconstrict) which reduces the amount of blood flow through the area and limits the amount of blood loss. Collagen is exposed at the site of injury, the collagen promotes platelets to adhere to the injury site. Platelets release cytoplasmic granules which contain serotonin, ADP and thromboxane A2, all of which increase the effect of vasoconstriction. The spasm response becomes more effective as the amount of damage is increased. Vascular spasm is much more effective in smaller blood vessels. Platelet plug formation: Bone-marrow cells can be mobilized into the circulation during which myeloid-and megakaryocyte-biased progenitors and mature megakaryocytes may enter the bloodstream. Platelets derived from these megakaryocytes contribute broadly to hemostasis, thrombosis, inflammation, and vascular biology through platelet generation. Platelets adhere to damaged endothelium to form a platelet plug (primary hemostasis) and then degranulate. This process is regulated through thromboregulation. Plug formation is activated by a glycoprotein called von Willebrand factor (vWF), which is found in plasma.
=== Odor === Kimchi is known for its strong, spicy, flavors and odors, although milder varieties exist. Variations in the fermentation process cause the final product to be highly variable in terms of quality and flavor. The strong odor is especially tied to the sulfur compounds from garlic and ginger of kimchi, which can be less appealing to non-Koreans. Thus, scientists are experimenting with the types of bacteria used in its production to minimize the odor to increase the appeal to international markets. These efforts are not universally appreciated by lovers of kimchi, as the flavor is affected in the process, and some see that "South Korea's narrative about its own culinary staple" is being manipulated to suit the foreigners' tastes.
Glycoproteins have differential levels of glycosylations and adsorb SDS more unevenly at the glycosylations, resulting in broader and blurred bands. Membrane proteins, because of their transmembrane domain, are often composed of the more hydrophobic amino acids, have lower solubility in aqueous solutions, tend to bind lipids, and tend to precipitate in aqueous solutions due to hydrophobic effects when sufficient amounts of detergent are not present. This precipitation manifests itself for membrane proteins in a SDS-PAGE in "tailing" above the band of the transmembrane protein. In this case, more SDS can be used (by using more or more concentrated sample buffer) and the amount of protein in the sample application can be reduced. An overloading of the gel with a soluble protein creates a semicircular band of this protein (e. g. in the marker lane of the image at 66 kDa), allowing other proteins with similar molecular weights to be covered. A low contrast (as in the marker lane of the image) between bands within a lane indicates either the presence of many proteins (low purity) or, if using purified proteins and a low contrast occurs only below one band, it indicates a proteolytic degradation of the protein, which first causes degradation bands, and after further degradation produces a homogeneous color ("smear") below a band. The documentation of the banding pattern is usually done by photographing or scanning. For a subsequent recovery of the molecules in individual bands, a gel extraction can be performed.
Investigating the use of standardized HPLC methods, Valko's 2016 research suggested that Chromatographic properties measured at early stages of the drug discovery process can assess lipophilicity, oral absorption, volume of distribution, drug efficiency, and even early dose estimation. In related research, she introduced standardized procedures for accelerating drug discovery by evaluating in vivo distribution and non-specific binding through chromatographic profiling of analogs, highlighting the advantages over traditional metrics such as Ligand Lipophilicity Efficiency (LLE). Later, her 2018 work tackled peptide therapeutic challenges by assessing biomimetic properties like lipophilicity and membrane affinity via High-Performance Liquid Chromatography, using chemically bonded protein and immobilized artificial membrane stationary phases. Her 2021 suggested that membrane and alpha-1-acid glycoprotein retention can be considered as promising indices for assessing the ecotoxicological risk of drugs, with membrane models showing superior performance compared to those derived from the traditional octanol-water system. In addition, she also proposed a model using biomimetic HPLC methods and measured binding properties to predict hERG inhibition, addressing early screening for potential cardiotoxicity and reducing late-stage failures in drug discovery.
Sources: en.wikipedia.org
Some authors have criticized the rule of five for the implicit assumption that passive diffusion is the only important mechanism for the entry of drugs into cells, ignoring the role of transporters. For example, O'Hagan and co-authors wrote as follows:This famous "rule of 5" has been highly influential in this regard, but only about 50 % of orally administered new chemical entities actually obey it. Studies have also demonstrated that some natural products break the chemical rules used in Lipinski filters such as macrolides and peptides.
Subsequent to the initial publication in the Lancet, three letters to the editor and a response from the authors extended the analysis. The issue of contention is whether thiopental, like many lipid-soluble drugs, may be redistributed from blood into tissues after death, effectively lowering thiopental concentrations over time, or whether thiopental may distribute from tissues into the blood, successfully increasing postmortem blood concentrations over time. Given the near absence of scientific, peer-reviewed data regarding thiopental postmortem pharmacokinetics, the controversy continues in the lethal-injection community, and, in consequence, many legal challenges to lethal injection have not used the Lancet article. In 2007, the same group that authored the Lancet study extended its study of the lethal-injection process through a critical examination of the pharmacology of the barbiturate thiopental. This study – published in the online journal PLOS Medicine – confirmed and extended the conclusions made in the original article and goes further to disprove the assertion that the lethal-injection process is painless. To date, these two studies by the University of Miami team serve as the only critical peer-reviewed examination of the pharmacology of the lethal-injection process.
=== Federal funding === Canada's National Research Council (NRC) provided Providence Therapeutics with CAD$5 million for the launch of January 2021 first phase of PTX-COVID19-B clinical trials. As part of the federal government's "next generation manufacturing supercluster" program, Providence and Northern mRNA had also been "cleared to access up to $5 million" towards the manufacturing start up process, according to a federal government spokesperson. The CBC report in late April 2021 also stated that "it could be eligible for a slice of $113 million in additional funding from the National Research Council of Canada Industrial Research Assistance Program". The federal government had provided funding to some other companies in Canada that were also working to develop a COVID-19 vaccine. Sorenson as Providence Therapeutics CEO posted an open letter to Prime Minister Justin Trudeau, in which he requested $CDN 150 million upfront to be used to pay for clinical trial and material costs. On April 29, 2021, Sorenson appeared before the House of Commons standing committee on international trade, to ask the Minister of Procurement, Anita Anand, to consider PTX-COVID19-B as an alternative to Moderna and Pfizer for the "2022 booster vaccines". Sorenson said that the NRC had approached Providence Therapeutics in 2020 after the company had announced their Phase I trial PTX-COVID19-B. Sorenson told the Standing Committee that, "We've had really good dialogue ever since phase I started. That process has gone on.
Sources: en.wikipedia.org
== Early life == Peters was born Braden Eric Peters to a businessman father and stay-at-home mother. He was raised in Hoboken, New Jersey, and attended Seton Hall Preparatory School in West Orange, New Jersey. He has stated that he became interested in looksmaxxing—a term originating on incel message boards in the early 2010s that describes the process of making oneself as physically attractive as possible—in high school, which he has attributed to wanting to influence others politically by becoming more attractive. Peters described his life during the COVID-19 lockdowns as being "online for 14 hours a day", browsing looksmaxxing forums, playing Grand Theft Auto V and skipping online classes. Peters has stated in interviews that he would often hide his testosterone supplements from his parents, and when caught, he would be sent to live with his grandmother. Peters claims to have been expelled after "just three weeks" from Sacred Heart University in Fairfield, Connecticut for his use of "peptides and 'roids".
In cladistics, a homoplasy is a trait shared by two or more taxa for any reason other than that they share a common ancestry. Taxa which do share ancestry are part of the same clade; cladistics seeks to arrange them according to their degree of relatedness to describe their phylogeny. Homoplastic traits caused by convergence are therefore, from the point of view of cladistics, confounding factors which could lead to an incorrect analysis.
MnO−4 + 8 H+ + 5 e− ⇌ Mn2+ + 4 H2O to be taken into account. The equilibrium constant for a full redox reaction can be obtained from the standard redox potentials of the constituent half-reactions. At equilibrium the potential for the two half-reactions must be equal to each other and, of course, the number of electrons exchanged must be the same in the two half reactions. Redox equilibrium play an important role in the electron transport chain. The various cytochromes in the chain have different standard redox potentials, each one adapted for a specific redox reaction. This allows, for example, atmospheric oxygen to be reduced in photosynthesis. A distinct family of cytochromes, the cytochrome P450 oxidases, are involved in steroidogenesis and detoxification.
A ligand is a molecule utilized for cell-signaling that binds to a target tissue for cellular communication. There are many different types of ligands, including internal receptors, cell surface receptors, ion channel receptors, G protein-coupled receptors (GPCRs), and enzyme-linked receptors. Ligands can be divided into two categories, agonists or antagonists. Agonists behave similarly to natural ligands, while antagonists are inhibitors and block the binding of the natural ligand. There are many different subtypes of agonists, including endogenous agonists, super agonist, full agonist, inverse agonist, and irreversible agonist. Radioligands are made up of the radioisotope, linker, and ligand. This structure allows the compound to identify and bind to the target tissue while retaining the ability to be tracked and imaged clinically. When a radioligand binds to its target, it alters the microenvironment of the receptor and surrounding tissue, partially due to the structure of the radioligand itself. Without both the high affinity ligand and the radioisotope, the efficiency of this process is lost.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.